PRAC published highlights of April 2017 meeting

The European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee (PRAC) has released highlights from their monthly meeting held on 3-6 April 2017.

The committee concluded a safety evaluation of selexipag, used for the treatment pulmonary arterial hypertension.  The short summary also details the ongoing Article 31 referrals.

To read the highlights and access the full, rather lengthy agenda for the meeting, please click here.